search  
 


Home

Who are we?

Why
register?


Signup for
registration


Online registration

Log in to register
your trial


Search a trial

NRT en CCMO

Contact

NEDERLANDS





MetaRegister
van CCT (UK)


ISRCTN-Register
van CCT (UK)


MelaMag Multicentre Trial


- candidate number14898
- NTR NumberNTR3997
- ISRCTNISRCTN wordt niet meer aangevraagd.
- Date ISRCTN created
- date ISRCTN requested
- Date Registered NTR16-mei-2013
- Secondary IDsP13-14 NL 43706.044.13
- Public TitleMelaMag Multicentre Trial
- Scientific TitleMELAMAG Trial: SentiMAG Melanoma - Sentinel Node Biopsy using Magnetic Nanoparticles: A prospective multicentre feasibility non-randomised clinical trial to compare sentinel node biopsy using magnetic nanoparticles vs. standard technique
- ACRONYM
- hypothesisThe new technique for sentinel node biopsy is non-inferior to the standard technique used.
- Healt Condition(s) or Problem(s) studiedSentinel Lymph Node Biopsy (SLNB), MRI, SentiMag, Sienna+
- Inclusion criteriaPatients with primary cutaneous melanoma scheduled for SLNB and who are clinically AJCC stage IB-IIC. - Patients available for follow-up for at least 12 months.
- Exclusion criteria Intolerance / hypersensitivity to iron or dextran compounds.
- Patients who cannot / do not receive radioisotope for SLNB.
- Patients with an iron overload disease.
- Patients with pacemakers or other implantable devices in the chestwall.
- Intolerance / hypersensitivity to patent blue dye in the centres where this is used routinely.
- Patients who had previous surgery to the likely draining lymph node fields.
- Patients with surgical scars between the primary biopsy site and the draining lymph node field(s) that may alter the lymphatic drainage.
- Patients with pre-existing lymphedema at the primary biopsy site, either primary or secundary.
- Patients who subsequently shown to have more than stage III disease.

Exclusion criteria MRI-subprotocol:
- Presence of implantable devices (electronically, magnetically, mechanically activated. E.g: cardioverter defibrillators, cardiac pacemakers)
- Metallic splinters in the eye.
- Ferromagnetic haemostatic clips in the central nervous system.
- Claustrophobia. MRI should be avoided in the presence of relative contraindications for MRI: cochlear implants, other pacemakers, insulin pumps and nerve stimulators, prosthetic heart valves, lead wires or similar wires in-situ.
- mec approval receivedno
- multicenter trialyes
- randomisedno
- group[default]
- Type2 or more arms, non-randomized
- Studytypeintervention
- planned startdate 1-jun-2013
- planned closingdate1-dec-2014
- Target number of participants176
- InterventionsThe Medisch Spectrum Twente will participate in the MRI subprotocol. As part of the MRI subprotocol, patients will undergo an MRI scan prior to the scheduled operation. The scan will take roughly 60 minutes and involves lying down in a tubular scanner. Once positioned in the scanner, an initial scan will be undertaken. Following the initial scan, a subcutaneous injection of 0,5-1mL Sienna+ near the tumour is given and a second scan is performed. The scan may need to be repeated at 2 hours or at 24 hours after the initial scan but further injections will not be required.

The operation will be performed as already planned by the surgeon. In addition to the normal patent blue dye and radioactive injection, an additional injection of Sienna+ is administered close to the tumour (an additional Sienna+ injection is only required if the MRI was undertaken over 24 hours prior to surgery). During surgery, the sentinel nodes will be detected with the normal detector (gamma probe), the magnetometer (SentiMag) and visually (blue and black-brown colour). The detected nodes will be excised and are taken to the University of Twente for quantitative magnetometer measurements. After the measurement the lymph nodes are send to the histopathology laboratory for analysis. The analysis in the laboratory is performed routinely and does not form part of this study.
- Primary outcomeThe primary endpoint: The proportion of sentinel nodes detected (detection rate) with either the standard (patent blue dye and radioisotope; or radioisotope alone) or the new technique (magnetic tracer and hand-held magnetometer).
- Secondary outcomeSecundary outcome measurements:
Morbidity from SLNB including lymphoedema, numbness, seroma, infection, cutaneous staining, chronic pain and early locoregional recurrence.

Outcome measurements MRI subprotocol: evaluate the accuracy of MRI for the localisation of the SLN.
- TimepointsThe study in the Medisch Spectrum Twente will include 30 patients in the period from 01-06-2013 until 01-12-2014
- Trial web siteN/A
- statusplanned
- CONTACT FOR PUBLIC QUERIES
- CONTACT for SCIENTIFIC QUERIES J.M. Klaase
- Sponsor/Initiator King's College London, Guy's & St Thomas' NHS Foundation Trust
- Funding
(Source(s) of Monetary or Material Support)
Technology Strategy Board CR&D - Biomedical Catalyst: Feasibility Award , Medisch Spectrum Twente, the University of Twente funds the MRI study and the Sienna+ injected.
- Publications
- Brief summaryThe MelaMag Mutlicenter Trial is a phase II paired equivalence trial. It will initially involve 6 centres and will be coordinated from King's College London (Guy's Hospital) by the Chief Investigator. The trial aimed to recruit 160 patients. Centres will be invited to recruit 30 patients and the trial will be closed once the target number of 160 complete patient datasets has been reached.

Patients will receive a radioisotope injection and a subcutaneous injection of Sienna+ close to the tumour. This may be given between up to thirty minutes before surgery. In centres that also participate in the MRI subprotocol, patients will undergo a pre-operative MRI before and after the injection of Sienna+. Ath the Medisch Spectrum Twente pre-operative MRI scans will be performed depending on the availability of the MRI scanning slots.

Intra-operatively, patients will receive an intradermal injection of patent blue (Guerbet, Parijs). All sentinel nodes detected intra-operatively using either the gamma probe or SentiMag; or demonstrating blue or black staining will be excised. In the lead centre (and any other sites participating in the MRI subprotocol), ex-vivo MRI scans of the excised nodes will be undertaken using a high-resolution MRI scanner. In the Medisch Spectrum Twente an ex-vivo MRI scan of the excised nodes is not possible. At the University of Twente in Enschede the amount of iron in each excised node will be measured using a quantitative magnetometer.

All lymph nodes will be assessed histologically and the nodal status will be related back to the SLNB detection rate with each technique.

Patients will be followed post-operatively (7-14 days after surgery) to assess if staining occurs or for any other adverse event. If staining is present, photographs will be taken. Further follow-up is at 3 months and at 1 year. Patients will be followed up for a total of 5 years, in accordance with current local policies.
- Main changes (audit trail)
- RECORD16-mei-2013 - 28-mei-2013


  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar nederlands@trialregister.nl